Clinical and research data in the past 20 years reveal that cyclooxygenase (COX)2 is overexpressed in a variety of malignant tumors (6–8) and are linked to apoptosis resistance (9), invasive tumor behavior (10) and the poor prognosis of breast cancer (8,11,12). This evidence concerns the gene PTGS2 and breast carcinoma.